31 March 2020
A Statement from Carter BloodCare on Convalescent Plasma

Blood Center participating in investigational use at request of physicians

Carter BloodCare is working with doctors and hospitals to facilitate the collection of convalescent plasma under the U.S. Food and Drug Administration’s (FDA) Emergency Investigational New Drug (eIND) guidance. The FDA’s web site outlines the protocols for physicians who want to participate in the Investigational COVID-19 Convalescent Plasma - Emergency INDs.

According to the FDA web site, “One investigational treatment being explored for COVID-19 involves the use of convalescent plasma collected from recovered COVID-19 patients. It is possible that convalescent plasma that contains antibodies to SARS-CoV-2 (the virus that causes COVID-19) might be effective against the infection.”

Carter BloodCare has specialized equipment and the staff with expertise to collect plasma from individuals identified by their doctors as having a suitable concentration of antibodies to the coronavirus causing COVID-19. In addition to satisfying the blood center’s donor criteria, these individuals must also satisfy additional FDA criteria that include resolution of symptoms for at least 14 days and negative results for COVID-19 on sophisticated testing. Carter BloodCare does not recruit these convalescent plasma donors; they are identified by physicians at area hospitals.

The FDA web site says that “although promising, convalescent plasma has not been shown to be effective in every disease studied. It is therefore important to determine through clinical trials, before routinely administering convalescent plasma to patients with COVID-19, that it is safe and effective to do so.”

Carter BloodCare’s mission is ‘We save lives by making transfusion possible.’ Collecting convalescent plasma from COVID-19 survivors is another way that we can help save lives. We are pleased to be of service to doctors and their patients.